Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-134041 · Präparat HOS-097520
Intravenously administered Midazolam is primarily midazolam (1 mg single dose)/ metabolised by CYP3A. Due to Tenofovir alafenamide (25 mg the presence of cobicistat, once daily) co-administration with Genvoya may result in increased plasma concentrations of this medicinal product, which is associated with the potential for serious or life-threatening adverse reactions. ANTI-GOUT Colchicine Interaction not studied with any of Dose reductions of colchicine may the components of Genvoya. be required. Genvoya should not be co-administered with colchicine to Co-administration with Genvoya patients with renal or hepatic may result in increased plasma impairment. concentrations of this medicinal product. N/A = not applicable
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): colchicine (HOS-086147) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 11ce8c7520a63dbe3698e9dac4617fc74704beb172e4a279f44017d5c4495c7b · Zeichen 49584–50827 im Abschnitt